Bristol Myers Squibb (BMS; NYSE: BMY, Princeton, NJ) and Anthropic announced a strategic agreement to deploy Claude AI as the company’s shared intelligence platform across research, clinical development, manufacturing, commercial, and corporate functions, covering more than 30,000 BMS employees globally. Financial terms were not disclosed.
The partnership centers on Claude Enterprise, Anthropic’s enterprise AI platform, which BMS will deploy across the organization rather than within a single function or therapeutic area. The rollout includes Claude Code, Anthropic’s software development toolset, which BMS engineering and data science teams will use to build and standardize internal AI capabilities.
BMS said the deployment is focused on accelerating software engineering, embedding AI-driven workflows into drug development, and connecting Claude to internal scientific, clinical, regulatory, manufacturing, and commercial data systems.
Across research and early development, Claude will be applied to proprietary scientific and molecular datasets spanning oncology, hematology, neuroscience, and immunology, with the aim of supporting target identification and optimization. In development operations, the platform is expected to assist with clinical study reports, patient safety narratives, and regulatory documentation, with BMS citing the potential to shorten timelines between data lock and regulatory filing. Manufacturing and quality teams will use the system for investigations, CAPA documentation, and batch release workflows, while commercial and medical affairs groups will use the platform to structure field insights and healthcare professional engagement data.